# US 10,556,967 B2 · Anti-ADAM28 antibody for treating cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,556,967 B2 - Document ID: US10556967B2 - Status: Granted - Kind: B2 - Application number: 15/815,148 - Filed: 2017-11-16 - Published: 2018-06-07 - Granted: 2020-02-11 - Earliest claimed: 2012-11-09 - Assignees: GeneFrontier Corporation; Keio University - Applicants: Genefrontier Corporation; Keio University - Inventors: Akira Miyakoshi; Rena Matsumoto; Shizue Katoh; Yuki Hayami; Satsuki Mochizuki; Masayuki Shimoda; Yasunori Okada - Web page: https://patentgrep.com/patent/US10556967B2 ## CPC - C07K 16/40: against enzymes - A61P 35/00: Antineoplastic agents - A61P 35/04: specific for metastasis - C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere} - A61K 2039/505: {comprising antibodies} - C07K 2317/21: from primates, e.g. man - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/55: Fab or Fab' - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody. ## Claims ### Claim 1 An antibody specifically binding to human ADAM28 and having an activity to inhibit enzyme activity of human ADAM28, which antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 5, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 7, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 8, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 9, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 10. ### Claim 2 (depends on 1) The antibody according to claim 1 wherein the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 17, and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 18. ### Claim 3 (depends on 1) A pharmaceutical composition comprising the antibody according to claim 1. ### Claim 4 (depends on 1) The antibody according to claim 1, wherein the antibody specifically binds to human ADAM28 at an epitope comprising the amino acid sequence shown in SEQ ID NO: 21. ### Claim 5 (depends on 2) A pharmaceutical composition comprising the antibody according to claim 2. ### Claim 6 (depends on 4) A pharmaceutical composition comprising the antibody according to claim 4. ### Claim 7 (depends on 1) A method of treating ADAM28 expressing cancer in a mammal, comprising administering an effective amount of the antibody according to claim 1 to the mammal. ### Claim 8 (depends on 7) The method according to claim 7, wherein the mammal is human. ### Claim 9 (depends on 7) The method according to claim 7, wherein the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 17, and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 18. ### Claim 10 (depends on 1) A method of inhibiting ADAM28 expressing cancer metastasis in a mammal, comprising administering an effective amount of the antibody according to claim 1 to the mammal. ### Claim 11 (depends on 10) The method according to claim 10, wherein the mammal is human. ### Claim 12 (depends on 10) The method according to claim 10, wherein the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 17, and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 18. ### Claim 13 (depends on 7) The method according to claim 7, wherein the antibody specifically binds to human ADAM28 at an epitope comprising the amino acid sequence shown in SEQ ID NO: 21. ### Claim 14 (depends on 10) The method according to claim 10, wherein the antibody specifically binds to human ADAM28 at an epitope comprising the amino acid sequence shown in SEQ ID NO: 21.